Subcutaneous Four-Week Dosing of the Novel Protein S Antibody VGA039 Demonstrates Safety and Clinically Meaningful Bleed Reduction in Patients with Von Willebrand Disease: Phase 1/2 Multi-Dose Study Results
Nicoletta C. Machin, Shrinath Kshirsagar, Adam Giermasz, Johnny Mahlangu, Gabriela Yamaguti-Hayakawa, Savita Rangarajan, Genevieve Moyer, Christine Kempton, Jane Mason, Michelle Sholzberg, Paula Villaça, Sandip Panicker, Eileen K. Sawyer, Gary Patou, Benjamin Kim, Allison P. Wheeler
Session: Short Talks - Emerging Therapeutics and Prophylactic Strategies in Coagulation Disorder - Short Talks (Live Event)

Evaluating pen-injector handling and PROs in patients switching from emicizumab to Mim8 in FRONTIER5
Johnny Mahlangu, Sanjay Ahuja, Erin Cockrell, Víctor Jiménez-Yuste, Michele Schiavulli, Amalie Rhode Høgh Nielsen, Camila Martins Mazini Tavares, Emily Waters, Cédric Hermans, Dan Johnson
Session: Posters/Exhibits/Break - Posters/Exhibits/Break (On-Demand)

FRONTIER3: Safety and efficacy of Mim8 prophylaxis in pediatric patients with hemophilia A
Johnny Mahlangu, M. Elaine Eyster, Karin Fijn van Draat, Gili Kenet, Nita Radhakrishnan, Irena Woznica-Karczmarz, Runhui Wu, Chur Woo You, Andrea Paramo Florencio, Jay Jay Thaung Zaw, Emily Waters, Manuel Carcao, Niki Patel
Session: Posters/Exhibits/Break - Posters/Exhibits/Break (On-Demand)

Mim8 Prophylaxis in Adults and Adolescents with Hemophilia A: 52-Week Efficacy and Safety Outcomes from the Phase 3 FRONTIER2 Study
Steven R Lentz, Aby Abraham, Cihan Ay, Anthony KC Chan, Victor Jiménez-Yuste, Johannes Oldenburg, Maria Elisa Mancuso, Johnny Mahlangu, Tadashi Matsushita, Lize van Vulpen, Renchi Yang, Amalie Rhode Høgh Nielsen, Ilgiz Rakhmatullin, Emily Waters, Pratima Chowdary, Maria Lage
Session: Posters/Exhibits/Break - Posters/Exhibits/Break (On-Demand)